- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01291316
GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation
In animal, the GABAergic system modulates central sensitisation, which is a key phenomenon in pain processing. The development of GABAA agonists targeting the subunits of the GABAA receptor implicated in nociception, but not the subunit implicated in sedation is attractive as it opens new perspectives of testing the role of GABAergic modulation of pain processing in human volunteers. The purpose of this subproject is to test the effect of the specific α2 and α3 agonist but sparing α1 effect TPA023 on a human model of peripheral and central sensitisation and to correlate its pharmacodynamic effect with the pharmacokinetic of the compound.
The results would contribute to clarify the potential role of these α2/α3 agonist but sparing α1drugs in clinical pain conditions.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
- To assess the effect of the GABAA agonist clobazam on central sensitisation (change in the size of the area of secondary hyperalgesia) in healthy volunteers.
- To assess the effect of the GABAA agonist clobazam on peripheral sensitisation.
- To assess the effect of the GABAA agonist clobazam on sedation.
- To correlate the pharmacokinetic of clobazam to its effect (PK-PD modelling)
- To describe the role of the polymorphisms of CYP450 2C19 in the pharmacokinetic and dynamic of clobazam.
Methodology :
phase II , exploratory, three arms randomised placebo-controlled, double blind cross-over study in healthy volunteers
Number of patients : 25
Test product,Dose, Route of administration :
Clobazam,20 mg,oral intake
Duration of treatment :
Single dose administration of each compound
Reference therapy :
Clonazepam 1mg, oral intake Tolterodine 1, 37mg, oral intake
Other therapy :
Flumazenil 0.2mg, intravenous
Efficacy evaluation :
Determination of the impact of clobazam:
- on the size of the area of secondary hyperalgesia induced by an UVB irradiation of the skin (sunburn model). The area is mapped with an electronical Von Frey filament
- on the pain threshold (heat, static and mechanical threshold) in the primary and secondary area of hyperalgesia
- on the nociceptive flexion reflex
- on tolerance pain threshold (cold pressor test)
- on the degree of sedation measured by saccadic eye movements, digit substation symbols test (DSST) and numerical rating scale.
- Determination of the concentration-time curve of clobazam and PK-PD modelling.
Statistical Methods :
Based on the results of a previous study done in our unit, assessing the effect of the association of paracetamol and ketorolac on the sunburn model30, the number of volunteers required to detect a 30% reduction in the area of hyperalgesia is 4830. However we chose a lower intensity of UVB irradiation than in previous studies. Using a dose of irradiation of 3 med , this number falls to 18, adopting a 5% level for statistical significance and a 80% power. Taking these two results in account we will go for 25 volunteers.
Data will be analysed by multifactorial analysis of variance (MANOVA) and by analysis of variance (ANOVA) with repeated measures In the case of withdrawal, the data obtained will not be used in the analysis. Data set will however be completed by enrolling a substitute volunteer.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Geneva, Switzerland, 1211
- University Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male subject, age between 18 and 60 year old
- Caucasian
- Type 3 skin phototype
- Non smoker or moderate smoker (< 10 cigarettes/day)
- No clinically abnormal findings on history and/or on physical examination
- Presence of an area of secondary hyperalgesia after UVB irradiation
Exclusion Criteria:
- Any concomitant illness
- Current or past history of drug and alcohol abuse or current intake of more than 3 glasses of alcohol a day or more than 21 glasses of alcohol per week
- Psychotropic drug intake during the last month
- Sun allergy or any skin disease
- Current and regular intake of any drugs that might affect nociception Paracetamol, or NSAIDS with a short half lives are permitted but should be stopped at least 48 h before the UVB session
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: clobazam
|
clobazam 20 mg, single oral dose
|
Active Comparator: clonazepam
|
clonazepam, 1 mg, single oral dose
|
Placebo Comparator: tolterodine
|
Tolterodine 1,37mg, single oral dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determination of the impact of clobazam on the change in the area of secondary hyperalgesia (in cm2) mapped with a Von Frey filament (256mN).
Time Frame: 3 single days spaced out with at least two weeks wash-out periods
|
3 single days spaced out with at least two weeks wash-out periods
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the pain threshold (heat (°C) static mechanical (g) and dynamic mechanical (Numerical rating scale NAS) in the area of secondary hyperalgesia
Time Frame: 3 single days spaced out with at least two weeks wash-out periods
|
3 single days spaced out with at least two weeks wash-out periods
|
|
Change in the pain threshold (heat (°C ) static mechanical (g) and dynamic mechanical (NAS)) in the area of primary hyperalgesia
Time Frame: 3 single days spaced out with at least two weeks wash-out periods
|
3 single days spaced out with at least two weeks wash-out periods
|
|
Change in Nociceptive Flexion Reflex
Time Frame: 3 single days spaced out with at least two weeks wash-out periods
|
3 single days spaced out with at least two weeks wash-out periods
|
|
Change in the latency and in the area under the pain intensity/time curve in cold pressor test
Time Frame: 3 single days spaced out with at least two weeks wash-out periods
|
3 single days spaced out with at least two weeks wash-out periods
|
|
Change in mean target saccades peak velocity, target saccades acceleration and deceleration, in saccade latency (msec), in saccadic accuracy, in smooth pursuit lead time and in the number of saccadic intrusions in the smooth pursuit.
Time Frame: 3 single days spaced out with at least two weeks wash-out periods
|
3 single days spaced out with at least two weeks wash-out periods
|
|
Change in the total number and in the correct number of symbols drawn in the DDST challenge.
Time Frame: 3 single days spaced out with at least two weeks wash-out periods
|
3 single days spaced out with at least two weeks wash-out periods
|
|
Time concentration curve evaluation: blood samples at 0,5, 1, 2, 4, 6, 8,12, and at 24 hours post-dose
Time Frame: 3 single days spaced out with at least two weeks wash-out periods
|
Clobazam and N-desmethylclobazam concentrations (µg/mL)
|
3 single days spaced out with at least two weeks wash-out periods
|
Pharmacokinetic/ pharmacodynamic modelling.
Time Frame: 3 single days spaced out with at least two weeks wash-out periods
|
3 single days spaced out with at least two weeks wash-out periods
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Neuralgia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Anticonvulsants
- GABA-A Receptor Agonists
- GABA Agonists
- Clonazepam
- Tolterodine Tartrate
- Clobazam
Other Study ID Numbers
- GABA-SPUM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathic Pain
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
University Hospital, Strasbourg, FranceTerminatedPostthoracotomy Pain | Postthoracoscopy Neuropathic PainFrance
-
AstraZenecaCompletedNociceptive Pain | Peripheral Neuropathic PainUnited Kingdom
-
University Malaysia SarawakPersatuan Diabetes MalaysiaCompletedNeuropathic Pain, Nociceptive PainMalaysia
-
University Hospital, Clermont-FerrandRecruitingPeripheral Neuropathic PainFrance
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Hospices Civils de LyonCompletedPharmacoresistant Neuropathic PainFrance
-
Yuhan CorporationCompletedPeripheral Neuropathic PainKorea, Republic of
-
University Hospital, Clermont-FerrandCompletedNeuropathic Pain RebelFrance
Clinical Trials on clobazam
-
Lundbeck LLCCompletedEpilepsy | Epilepsy, Generalized | SeizuresUnited States, Belarus, India, Australia, Lithuania
-
Lundbeck LLCCompletedEpilepsy | Epilepsy, Generalized | SeizuresUnited States
-
Boston Children's HospitalLundbeck LLCCompletedElectrical Status Epilepticus in SleepUnited States
-
University Hospital Inselspital, BerneCompleted
-
St. Joseph's Hospital and Medical Center, PhoenixH. Lundbeck A/SUnknownRefractory EpilepsyUnited States
-
Lars Kristian MunckPierre and Marie Curie UniversityCompletedBile Acid Malabsorption | Chronic DiarrheaDenmark
-
Instituto de Investigação em ImunologiaButantan InstituteUnknownCancer. | Melanoma. | Ovarian Cancer. | Lung Cancer.Brazil
-
Pavel KleinH. Lundbeck A/SUnknown
-
Hugo W. Moser Research Institute at Kennedy Krieger...Completed
-
H. Lundbeck A/STerminatedDravet SyndromeUnited States, Mexico